세계의 POC 지질검사 시장 : 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 적응 질환별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Point Of Care Lipid Test Market Size, Share & Trends Analysis Report By Product, By Application, By Disease Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,257,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,645,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,420,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 POC 지질검사 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 POC 지질검사 시장은 2030년까지 11억 달러에 이르고, 예측 기간 동안 CAGR 6.5%로 확대될 것으로 예측됩니다.

심혈관 질환, 당뇨병, 신장 장애와 같은 만성 질환의 유병률 증가는 시장 성장에 기여하는 주요 요인이며, 이러한 질병은 종종 효과적인 관리를 위해 빈번한 지질 모니터링이 필요합니다.

또한, 이러한 동향은 지질 불균형의 조기 발견이 장기적인 건강 위험을 완화하는 데 도움이 되는 예방 의료에 대한 광범위한 중점화와 일치하고 있습니다. 이러한 툴을 디지털 플랫폼과 통합함으로써 유행시에 기세를 늘린 원격 모니터링이 가능해져 불필요한 임상 진찰을 줄이기 위해 계속 유효합니다.

POC 지질검사 시장 보고서 및 하이라이트

• 소모품이 제품 부문을 지배하여 2024년에는 61.9%의 최대 매출 점유율을 차지했습니다.
• 장비는 예측 기간 동안 CAGR 6.6%를 보일 것으로 예측됩니다.
• 고지혈증은 2024년 46.9%의 최대 판매 점유율을 차지했습니다. 이것은 주로 당뇨병과 심혈관 질환과 같은 만성 질환의 신속하고 효과적인 관리의 필요성이 증가하고 있다는 배경에 있습니다.
• 고트리글리세리드혈증은 속도와 접근성을 향상시키는 검사기술의 급속한 개발로 예측기간 동안 CAGR 7.0%로 성장할 전망입니다.
• 지질 및 리포단백 장애가 시장을 석권해 2024년의 수익 점유율은 38.7%로 최대였습니다. 아테롬성 동맥경화증은 2025년부터 2030년까지 현저한 CAGR로 성장할 것으로 예측됩니다.
• 병원 부문은 시장에서 지배적인 지위를 차지했으며 2024년에는 32.2%로 가장 큰 수익 점유율을 차지했습니다. 병원은 적절한 진단과 만성 상태의 관리를 가능하게 하고 환자의 결과를 향상시키기 위해 신속하고 정확한 지질 검사가 필요합니다.
• 북미는 세계의 POC 지질검사 시장을 독점하고 2024년 43.6%의 최대 수익 점유율을 차지했습니다. 이는 주로 요점 관리를 원격 의료 플랫폼에 통합하여 사용 편의성과 환자 참여도를 높이기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계의 POC 지질검사 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 세계의 POC 지질검사 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 세계의 POC 지질검사 시장 : 제품 비즈니스 분석

• 제품 부문 대시보드
• POC 지질검사 시장 : 제품 변동 분석
• 세계의 POC 지질검사 시장 규모와 동향 분석(제품별, 2018-2030년)
• 기기
• 소모품

제5장 세계의 POC 지질검사 시장 : 용도별 비즈니스 분석

• 용도 부문 대시보드
• POC 지질검사 시장 : 용도 변동 분석
• 세계의 POC 지질검사 시장 규모와 동향 분석(용도별, 2018-2030년)
• 고지혈증
• 고트리글리세리드혈증
• 탄지에르병
• 고리포단백혈증
• 가족성 고콜레스테롤혈증
• 기타

제6장 세계의 POC 지질검사 시장 : 적응 질환별 비즈니스 분석

• 적응 질환 부문 대시보드
• POC 지질검사 시장 : 적응 질환 변동 분석
• 세계의 POC 지질검사 시장 규모와 동향 분석(적응 질환별, 2018-2030년)
• 지질 및 지단백질 질환
• 동맥경화증
• 간 및 신장의 질병
• 당뇨병
• 기타

제7장 세계의 POC 지질검사 시장 : 최종 용도별 비즈니스 분석

• 최종 용도 부문 대시보드
• POC 지질검사 시장 : 최종 용도 변동 분석
• 세계의 POC 지질검사 시장 규모와 동향 분석(최종 용도별, 2018-2030년)
• 병원
• 클리닉
• 조사 및 진단 실험실
• 기타

제8장 세계의 POC 지질검사 시장 : 지역별 추정 및 동향 분석

• 지역 시장 대시보드
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 세계의 POC 지질검사 시장 :주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • Key Company Heat Map Analysis, 2024
• 기업 프로파일
  • Callegari
  • Abbott Laboratories
  • MiCoBio
  • Nova Biomedical Corporation
  • VivaChek Biotech(Hangzhou) Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Menarini Group
  • SD Biosensor, Inc e

JHS

영문 목차

영문목차

Point Of Care Lipid Test Market Growth & Trends:

The global point of care lipid test market is anticipated to reach USD 1.1 billion by 2030 and is anticipated to expand at a CAGR of 6.5% over the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and kidney disorders is a key driver contributing to the market growth, as these conditions often necessitate frequent lipid monitoring for effective management. Cardiovascular complications remain a major concern for patients with kidney disease, where factors such as elevated lipid levels and systemic inflammation increase risks.

Furthermore, this trend aligns with the broader emphasis on preventive healthcare, where early detection of lipid imbalances helps mitigate long-term health risks. Portable testing devices enable real-time results at clinics, hospitals, or homes, streamlining patient care and empowering individuals to manage their health proactively. The integration of these tools with digital platforms supports remote monitoring, a practice that gained momentum during the pandemic and remains relevant for reducing unnecessary clinical visits.

Point Of Care Lipid Test Market Report Highlights:

• Consumables dominated the product segment and accounted for the largest revenue share of 61.9% in 2024. This is attributed to the need for disposable and single-use consumables for rapid, user-friendly testing procedures.
• Instruments are expected to grow at a CAGR of 6.6% over the forecast period, owing to contemporary analyzers' improved accuracy, mobility, and connectivity features, which make them perfect for decentralized situations.
• The hyperlipidemia held the largest revenue share of 46.9% in 2024, primarily driven by the rising necessity for quick, effective management of chronic diseases such as diabetes and cardiovascular disease.
• Hypertriglyceridemia is expected to grow at a CAGR of 7.0% over the forecast period, owing to the rapid developments in testing technologies that improve speed and accessibility.
• Lipid and lipoprotein disorders dominated the market, with the largest revenue share of 38.7% in 2024. Atherosclerosis is expected to grow at a significant CAGR from 2025 to 2030.
• The hospitals segment held the dominant position in the market and accounted for the largest revenue share, 32.2%, in 2024. Hospitals need quick, precise lipid testing to allow appropriate diagnosis and management of chronic situations, enhancing patient outcomes.
• North America dominated the global point-of-care lipid test market and accounted for the largest revenue share of 43.6% in 2024, primarily due to the incorporation of point-of-care testing with telehealth platforms, which improves user-friendliness and patient engagement.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Disease Indication
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Disease Indication Outlook
  • 2.2.4. End Use Outlook
  • 2.2.5. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Point of Care Lipid Test Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Global Point of Care Lipid Test Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Global Point of Care Lipid Test Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Point of Care Lipid Test Market: Product Movement Analysis
• 4.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Consumables
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Global Point of Care Lipid Test Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Point of Care Lipid Test Market: Application Movement Analysis
• 5.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Application, 2018 to 2030 (USD Million)
• 5.4. Hyperlipidemia
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Hypertriglyceridemia
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Tangier Disease
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Hyperlipoproteinemia
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.8. Familial Hypercholesterolemia
  • 5.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Global Point of Care Lipid Test Market: Disease Indication Business Analysis

• 6.1. Disease Indication Segment Dashboard
• 6.2. Point of Care Lipid Test Market: Disease Indication Movement Analysis
• 6.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By Disease Indication, 2018 to 2030 (USD Million)
• 6.4. Lipid and Lipoprotein Disorders
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Atherosclerosis
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Liver and Renal Diseases
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Diabetes Mellitus
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Global Point of Care Lipid Test Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Point of Care Lipid Test Market: End Use Movement Analysis
• 7.3. Global Point of Care Lipid Test Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Clinics
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Research and Diagnostic Laboratories
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Global Point of Care Lipid Test Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Global Point of Care Lipid Test Market by Regional: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key Country Dynamics
    • 8.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.1.3. Competitive Scenario
    • 8.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Germany
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.1.3. Competitive Scenario
    • 8.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.5.3. Competitive Scenario
    • 8.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.6.3. Competitive Scenario
    • 8.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.7.3. Competitive Scenario
    • 8.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 8.5.8.3. Competitive Scenario
    • 8.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.1.3. Competitive Scenario
    • 8.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Thailand
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key Country Dynamics
    • 8.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.7.1.3. Competitive Scenario
    • 8.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.7.2.3. Competitive Scenario
    • 8.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. South Africa
    • 8.8.1.1. Key Country Dynamics
    • 8.8.1.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.1.3. Competitive Scenario
    • 8.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.2.3. Competitive Scenario
    • 8.8.2.4. South Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.3.3. Competitive Scenario
    • 8.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 8.8.4.3. Competitive Scenario
    • 8.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key Company Heat Map Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Callegari
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Abbott Laboratories
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. MiCoBio
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Nova Biomedical Corporation
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. VivaChek Biotech (Hangzhou) Co., Ltd.
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. F. Hoffmann-La Roche Ltd.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Menarini Group
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. SD Biosensor, Inc e
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives

관련자료